دورية أكاديمية
[Drugs that may trigger or exacerbate myasthenia gravis].
| العنوان: | [Drugs that may trigger or exacerbate myasthenia gravis]. |
|---|---|
| عنوان ترانسليتريتد: | Medikamenter som kan utløse og forverre myasthenia gravis. |
| المؤلفون: | Elsais A; Nevrologisk avdeling, Oslo universitetssykehus, Rikshospitalet, Norway. ahmed.elsais@medisin.uio.no, Popperud TH, Melien Ø, Kerty E |
| المصدر: | Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke [Tidsskr Nor Laegeforen] 2013 Feb 05; Vol. 133 (3), pp. 296-9. |
| نوع المنشور: | Journal Article |
| اللغة: | Norwegian |
| بيانات الدورية: | Publisher: Norske Laegeforening Country of Publication: Norway NLM ID: 0413423 Publication Model: Print Cited Medium: Internet ISSN: 0807-7096 (Electronic) Linking ISSN: 00292001 NLM ISO Abbreviation: Tidsskr Nor Laegeforen Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Oslo : Norske Laegeforening Original Publication: Chistiania : Alb. Cammermeyer, 1880- |
| مواضيع طبية MeSH: | Myasthenia Gravis/*chemically induced, Acetylcholine/metabolism ; Adrenal Cortex Hormones/adverse effects ; Adrenergic beta-Antagonists/adverse effects ; Aminoglycosides/adverse effects ; Analgesics/adverse effects ; Anesthetics/adverse effects ; Anti-Infective Agents/adverse effects ; Anticonvulsants/adverse effects ; Botulinum Toxins/adverse effects ; Contraindications ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects ; Lithium/adverse effects ; Macrolides/adverse effects ; Magnesium Sulfate/adverse effects ; Muscle Weakness/chemically induced ; Muscle Weakness/physiopathology ; Myasthenia Gravis/physiopathology ; Neuromuscular Junction/drug effects ; Neuromuscular Junction/metabolism ; Penicillamine/adverse effects ; Receptors, Cholinergic/drug effects ; Receptors, Cholinergic/metabolism ; Vaccines/adverse effects |
| مستخلص: | Myasthenia gravis (MG) is an autoimmune disease causing muscle weakness due to impaired transmission at the neuromuscular junction. MG or a MG-like condition may be triggered or exacerbated by several drugs used for treatment of other diseases. Drugs may interfere with the neuromuscular transmission through several mechanisms, either by affecting pre- or postsynaptic ion channels or by affecting acetylcholinesterase. Based on a literature search in PubMed and the authors' own clinical experiences, we provide an overview focusing on the most frequently used drugs that may exacerbate weakness in patients with MG. In our experience, symptomatic MG-patients who have a generalised disease are especially vulnerable to drug-induced exacerbations, while stable MG patients with few symptoms more seldom are. Nevertheless, patients with MG must receive treatment for co-existing conditions. It is important to be aware of a possible increase in muscle weakness when introducing a new drug. If the patient deteriorates, the new treatment must be withdrawn or the dose reduced. |
| المشرفين على المادة: | 0 (Adrenal Cortex Hormones) 0 (Adrenergic beta-Antagonists) 0 (Aminoglycosides) 0 (Analgesics) 0 (Anesthetics) 0 (Anti-Infective Agents) 0 (Anticonvulsants) 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors) 0 (Macrolides) 0 (Receptors, Cholinergic) 0 (Vaccines) 7487-88-9 (Magnesium Sulfate) 9FN79X2M3F (Lithium) EC 3.4.24.69 (Botulinum Toxins) GNN1DV99GX (Penicillamine) N9YNS0M02X (Acetylcholine) |
| تواريخ الأحداث: | Date Created: 20130206 Date Completed: 20130419 Latest Revision: 20181202 |
| رمز التحديث: | 20231215 |
| DOI: | 10.4045/tidsskr.12.0624 |
| PMID: | 23381166 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 0807-7096 |
|---|---|
| DOI: | 10.4045/tidsskr.12.0624 |